NCT02426333View on ClinicalTrials.gov

Optimizing Abiraterone Therapy

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 24, 2019

Study Completion Date

August 1, 2019

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
OTHER

Abiraterone Acetate

Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)

Trial Locations (3)

Unknown

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

Canisius Wilhelmina Ziekenhuis, Nijmegen

Radboud UMC, Nijmegen

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT02426333 - Optimizing Abiraterone Therapy | Biotech Hunter | Biotech Hunter